Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.71 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.69 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.66 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.61 |
| ▸ | EP300 | Q09472 | 1/20 | 0.56 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.56 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5718523 | 0.84 | G6PD (0.69) | G6PDHCRTR1HKDC1HSD17B2ERN1 | |
| SCHEMBL30733446 | 0.84 | G6PD (0.69) | G6PDHCRTR1HKDC1HSD17B2ERN1 | |
| SCHEMBL3259256 | 0.83 | G6PD (1.00) | G6PDHCRTR1HKDC1HSD17B2EP300 | |
| SCHEMBL3260281 | 0.82 | HCRTR1 (1.00) | G6PDHCRTR1HKDC1HSD17B2HTT | |
| SCHEMBL23141177 | 0.80 | WDR5 (0.54) | G6PDHCRTR1HKDC1KEAP1CYP1A2 | |
| SCHEMBL829587 | 0.80 | HCRTR1 (0.48) | G6PDHCRTR1HKDC1HSD17B2KEAP1 | |
| SCHEMBL3259564 | 0.80 | G6PD (0.76) | G6PDHCRTR1HKDC1HSD17B2SLC40A1 | |
| SCHEMBL3260797 | 0.80 | HKDC1 (1.00) | G6PDHCRTR1HKDC1HSD17B2EP300 | |
| SCHEMBL1806259 | 0.77 | ABCC9 (0.59) | G6PDHCRTR1HKDC1HSD17B2PTPN22 | |
| SCHEMBL15894595 | 0.76 | KEAP1 (0.64) | G6PDHCRTR1HKDC1EP300KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | PTC THERAPEUTICS, INC. | 2008-10-23 | — | — | US | claimed |
| EP-1828195-A2 | SUBSTITUTED PHENOLS AS ACTIVE AGENTS INHIBITING VEGF PRODUCTION | PTC Therapeutics, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006065479-A2 | SUBSTITUTED PHENOLS AS ACTIVE AGENTS INHIBITING VEGF PRODUCTION | PTC THERAPEUTICS, INC. (US) | 2006-06-22 | — | — | WO | claimed |
| US-8143257-B2 | inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester | PTC THERAPEUTICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143257-B2 | inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester | PTC THERAPEUTICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143257-B2 | inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester | PTC THERAPEUTICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | PTC THERAPEUTICS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | PTC THERAPEUTICS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | PTC THERAPEUTICS, INC. | 2008-10-23 | — | — | US | disclosed |
| EP-1828195-A2 | SUBSTITUTED PHENOLS AS ACTIVE AGENTS INHIBITING VEGF PRODUCTION | PTC Therapeutics, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006065479-A2 | SUBSTITUTED PHENOLS AS ACTIVE AGENTS INHIBITING VEGF PRODUCTION | PTC THERAPEUTICS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | VEGFA, FLT4, FLT1 | G6PD 1215/4885HCRTR1 4632/4885HKDC1 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.